**Supplemental Digital Content 10: Ocular (study eye) and nonocular serious adverse events up to month 12 regardless of study drug relationship (Safety set\*)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Preferred term, n (%)** | **Ranibizumab 0.5 mg (n = 119)** | **Sham with ranibizumab 0.5 mg(n = 52)** | **Total(N = 178)** |
| **Ocular SAEs, total** | **0** | **0** | **0** |
| **Nonocular SAEs, total** | **8 (6.7)** | **4 (7.7)** | **12 (6.7)** |
| Abdominal pain upper | 1 (0.8) | 0 | 1 (0.6) |
| Acute respiratory failure | 1 (0.8) | 0 | 1 (0.6) |
| Atrial fibrillation | 1 (0.8) | 0 | 1 (0.6) |
| Intraductal papilloma of breast | 1 (0.8) | 0 | 1 (0.6) |
| Invasive lobular breast carcinoma | 1 (0.8) | 0 | 1 (0.6) |
| Parkinsonism | 1 (0.8) | 0 | 1 (0.6) |
| Peripheral artery stenosis | 1 (0.8) | 0 | 1 (0.6) |
| Pituitary tumor benign | 1 (0.8) | 0 | 1 (0.6) |
| COPD | 0 | 1 (1.9) | 1 (0.6) |
| Fecaloma | 0 | 1 (1.9) | 1 (0.6) |
| Hepatocellular carcinoma | 0 | 1 (1.9) | 1 (0.6) |
| Oliguria | 0 | 1 (1.9) | 1 (0.6) |
| Pyrexia | 0 | 1 (1.9) | 1 (0.6) |
| Rheumatic disorder | 0 | 1 (1.9) | 1 (0.6) |
| Urosepsis | 0 | 1 (1.9) | 1 (0.6) |
| **Death** | **0** | **0** | **0** |
| \*Consisted of all adult patients who received at least one application of study treatment and had at least one post-baseline safety assessment.No SAEs were reported for patients in the sham without ranibizumab group. Preferred terms are sorted in descending order of frequency of the ranibizumab 0.5 mg group. A patient with multiple occurrences of a preferred term is counted only once in the preferred term row. COPD, chronic obstructive pulmonary disorder; SAE, serious adverse event |